What Happens When You Stop Ozempic: The Weight Regain Data

The Part of the Ozempic Story Nobody Advertises

The before-and-after photos are everywhere. Twenty, thirty, fifty pounds gone. What you don't see is the "after the after": what happens when people stop taking the shots.

And most people do stop. Cost, insurance changes, side effects, shortages, or simply feeling "done" once the weight is off. The question is what happens next, and the clinical trial data are clear: for most people, the weight comes back, and it comes back fast.

That's not a moral failing and it's not a reason to never use these drugs. It's how they work. But you should know exactly what you're signing up for before you start, and especially before you stop.

A quick note on names: Ozempic and Wegovy are both semaglutide (Ozempic is approved for type 2 diabetes, Wegovy for weight management). Mounjaro and Zepbound are both tirzepatide. Most people say "Ozempic" for all of them, so we will too, but the trials below name the specific drug.

The Trials That Stopped the Drug on Purpose

The best evidence comes from studies that deliberately switched some people off the drug and onto a placebo, without telling them, and then tracked their weight.

STEP 1 Extension: Two-Thirds Back in a Year

In the original STEP 1 trial, adults taking semaglutide 2.4 mg (Wegovy) for 68 weeks lost an average of 17.3% of their body weight. Then the drug and the trial's lifestyle program stopped, and researchers followed 327 of them for another year.

By week 120:

• They had regained 11.6 percentage points, about two-thirds of the weight they had lost.
• Their net loss from the start was just 5.6%.
• Most of the health improvements they'd gained, including in blood pressure, blood sugar and cholesterol, drifted back toward where they started.

STEP 4: Switch to Placebo, Weight Goes Up

STEP 4 took 803 people who had already spent 20 weeks on semaglutide and randomly split them. Over the next 48 weeks:

• Those who kept taking semaglutide lost another 7.9% of their body weight.
• Those switched to placebo regained 6.9%.

That's a gap of almost 15 percentage points, created entirely by whether the shot kept going.

SURMOUNT-4: Same Story With Tirzepatide

Tirzepatide (Mounjaro, Zepbound) is even more powerful, and the same thing happens when it stops. In SURMOUNT-4, published in JAMA in 2024, participants lost 20.9% of their body weight in the first 36 weeks. Then they were randomized for another year:

Fewer than 1 in 5 people who stopped kept most of their weight off. Nearly 9 in 10 who continued did.

The Big Picture: Back to Baseline in About 1.5 Years

In January 2026, researchers at the University of Oxford published the largest analysis yet in The BMJ: 37 studies covering 9,341 adults who had stopped weight-loss medication.

Their findings:

• Across all weight-loss drugs, people regained about 0.4 kg (0.9 lb) per month after stopping, putting them back at their starting weight within roughly 1.5 to 2 years.
• With the newer drugs, semaglutide and tirzepatide, regain was faster: about 0.8 kg (1.8 lb) per month, with a return to baseline in about 1.5 years.
• Weight came back faster after stopping a drug than after ending a diet-and-exercise program, regardless of how much weight people had lost.
• Improvements in blood sugar, blood pressure and cholesterol were estimated to return to baseline within about 1.4 years.

The bigger the loss, the more there is to regain, which is why the newer, stronger drugs show the steepest rebound.

Why the Weight Comes Back

GLP-1 drugs don't fix whatever drove the weight gain in the first place. They manage it, for as long as you take them.

These drugs mimic gut hormones that slow stomach emptying and turn down hunger and "food noise" in the brain. While you're on them, eating less feels easy. When you stop, those signals return to their old settings, and often louder, because your body is now actively defending against the weight you lost:

• Appetite returns. Hunger hormones that rise after weight loss are no longer being held down by the drug.
• You burn fewer calories than before. A smaller body needs less energy, and dieting tends to quietly lower your everyday movement as well. (We covered that in NEAT: The Calories You Burn Without Exercising.)
• Habits didn't have to change. If the drug did the work of eating less, there may be no new routine in place to take over when it stops.

This is why obesity specialists increasingly describe obesity as a chronic disease, like high blood pressure. Nobody expects blood pressure to stay down after they stop their blood pressure medication.

Most People Stop Anyway

Here's the uncomfortable reality. A 2025 study in JAMA Network Open followed 125,474 adults who started a GLP-1 drug:

• Among people without type 2 diabetes (in other words, taking it mainly for weight), 64.8% stopped within one year and 84.4% within two years.
• Stopping was more common among people with lower incomes, those 65 and older, and those with moderate or severe stomach side effects.
• Many restarted later, often after their weight started climbing again.

So the typical real-world pattern isn't "take it forever." It's "take it for a while, stop, regain, maybe restart."

The Hidden Risk: Losing Muscle, Regaining Fat

As we explained in Why You're Losing Muscle, Not Fat: The GLP-1 Drug Problem No One Talks About, a meaningful share of the weight lost on these drugs can be lean mass if you don't eat enough protein and lift weights.

That creates a worst-case scenario if you stop: you lose a mix of fat and muscle on the drug, then regain the weight, much of it likely as fat. You could end up around the same weight you started at, with less muscle and a lower metabolism than before. Research on exactly how regained weight is split between fat and muscle is still limited, but there's no good reason to take that risk.

Not Everyone Regains Everything

The trial numbers are averages, and real life is messier and, in some ways, more hopeful.

A 2025 Cleveland Clinic study of 7,938 adults, published in Diabetes, Obesity and Metabolism, tracked people for a year after they stopped semaglutide or tirzepatide. Among those taking the drugs for obesity, 45% maintained or kept losing weight, and the average regain was small. But there's a catch: many of them restarted the drug, switched to a different weight-loss medication or worked with a dietitian or exercise specialist. Support afterward made a big difference.

Exercise seems especially important. In a Danish trial published in eClinicalMedicine in 2024, people who had lost weight were assigned to a supervised exercise program, the GLP-1 drug liraglutide, both or neither for a year. All treatments then stopped. Over the following year:

• The drug-only group regained about 9.6 kg (21 lb).
• The exercise-only group regained about 3.6 kg (8 lb).
• The group that had done both kept more weight off and had a lower body-fat percentage than the drug-only group.

The drug didn't build habits. The exercise did.

If You're Thinking About Stopping

Never stop, switch or change the dose of a prescription drug without talking to your doctor first. But if you're planning to come off, here's what the evidence points to:

1. Have a plan before your last dose. Decide with your doctor whether you're stopping, cutting back, switching or taking a break, and how you'll monitor your weight.
2. Build the habits while you're still on the drug. Use the low-appetite period to practice the eating routine you'll need afterward, not just to eat less.
3. Lift weights and eat enough protein. Protect the muscle you have now. It's your best defense against a slower metabolism later.
4. Keep moving every day. Set a daily step floor and stick to it, especially as your appetite comes back.
5. Weigh yourself weekly, not daily. Set a clear line, for example 2–3% above your stopping weight, that triggers a call to your doctor.
6. Expect the hunger. It isn't weakness. It's biology. Plan high-protein, high-fiber meals so the return of appetite doesn't catch you off guard. (See Protein + Fiber = Weight Loss.)
7. Ask about tapering. Some doctors step the dose down gradually rather than stopping all at once. There isn't strong trial evidence yet that tapering prevents regain, but it may make the return of appetite easier to manage. Ask whether it makes sense for you.

Pro tip: Use our calculator to get your daily calorie target at your new, lower weight. It will be lower than what you used to eat, and knowing the number before you stop beats finding out from the scale.

The No-BS Takeaway

GLP-1 drugs are some of the most effective weight-loss treatments ever developed, but for most people they work only while you take them. In controlled trials, people who stopped regained about two-thirds of their lost weight within a year, and the latest Oxford analysis estimates most people are back at their starting weight in about a year and a half. Health benefits like lower blood pressure and blood sugar fade on a similar timeline.

That doesn't mean don't take them. It means go in with your eyes open: treat obesity as a long-term condition, build real habits while the drug makes it easier, protect your muscle, and never stop without a plan and your doctor's input.

Scientific References

1. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553–1564.
2. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425.
3. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48.
4. West S, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. The BMJ. 2026.
5. Rodriguez PJ, et al. Discontinuation and reinitiation of GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Network Open. 2025.
6. Cleveland Clinic Center for Value-Based Care Research. Real-world weight change after discontinuation of semaglutide or tirzepatide. Diabetes, Obesity and Metabolism. 2025.
7. Jensen SBK, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. eClinicalMedicine. 2024.